Search clinical trials for: Guanfacine Hydrochloride Immediate Release

Total 467 results

Rachel G. Greenberg, MD, MB, MHS
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Not yet recruiting

Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) (HYP01)

Hyperactivity in Children With Down Syndrome | Impulsivity in Children With Down Syndrome

United States
Shire

Completed

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder

United States, Canada
Maastricht University Medical Center
Shire

Completed

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity (SPD503-315)

Attention Deficit Disorder

Netherlands
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Shire

Completed

Guanfacine Immediate-release Electrocardiogram Results (QTc) Study

Healthy Volunteers

United States
Shire

Completed

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention-deficit/Hyperactivity Disorder

Spain, Belgium, United States, Netherlands, United Kingdom, Italy, Germany, Canada, France, Sweden
Shire

Completed

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Attention-Deficit/Hyperactivity Disorder

United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Shire

Completed

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Phobia, Social | Anxiety, Separation | Generalized Anxiety Disorder (GAD)

United States
Shire

Completed

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, Germany, Poland, Italy, Ukraine, Romania, United Kingdom, Sweden, Austria, Canada, France, Ireland
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Children's Specialized Hospital
Shire

Terminated

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Insomnia | Sleep Disorders | Attention-Deficit/Hyperactivity Disorder | Attention Deficit Disorder

United States
JPM van Stralen Medicine Professional

Completed

Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD

Attention Deficit Hyperactivity Disorder

Canada
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
Luye Pharma Group Ltd.

Recruiting

A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.

Generalized Anxiety Disorder

China
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Neurology Group of Bergen County, P.A.
Shire

Completed

Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine

Attention-deficit/Hyperactivity Disorder

United States
Maimonides Medical Center

Recruiting

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome (PWS-GXR)

Aggression | Behavioral Symptoms | Pathologic Processes | Nervous System Diseases | Obesity | Neurologic Manifestations | Neurobehavioral Manifestations | Congenital Abnormalities | Overnutrition | Nutrition Disorders | Genetic Diseases, Inborn | Intellectual Disability | Self-Injurious Behavior | Abnormalities, Multiple and other conditions

United States
The University of Texas Health Science Center at...
Shire

Completed

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

United States
NYU Langone Health
Winthrop University Hospital

Withdrawn

Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
Yale University
University of South Florida; New York University; Icahn School of Medicine at... and other collaborators

Completed

Guanfacine in Children With Tic Disorders

Tourette Syndrome | Tourette Disorder

United States
Alexion Pharmaceuticals

Completed

A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

Healthy

United States
Shanghai Mental Health Center

Not yet recruiting

Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression

Somatic Symptom

China
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
UConn Health
Yale University; Shire

Withdrawn

Guanfacine Extended Release and Mindfulness Skills Therapy

Stress Disorder

United States
Shire

Completed

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

ADHD

United States
APOGEPHA Arzneimittel GmbH

Completed

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

Urologic Diseases | Urinary Incontinence | Urinary Bladder, Neurogenic | Neurogenic Urinary Bladder Disorder | Bladder Disorder, Neurogenic | Urinary Bladder Disorder, Neurogenic | Neurogenic Bladder Disorder | Urinary Bladder Neurogenic Dysfunction | Overactive Detrusor Function

Romania, Austria, Germany
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States
Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, United Kingdom, Belgium, Germany, Netherlands, Portugal, Austria, Sweden
New York State Psychiatric Institute
Shire

Completed

Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder

Oppositional Defiant Disorder | Attention Deficit Disorder | Childhood Aggression | Intermittent Explosive Disorder

United States
Lori A. Schweickert, MD
Shire

Completed

Inuniv and Working Memory

Attention Deficit Hyperactivity Disorder

United States
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Rigshospitalet, Denmark
Karolinska Institutet; Academisch Medisch Centrum - Universiteit van Amsterdam... and other collaborators

Recruiting

Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

CLL

Denmark, Sweden, Netherlands
Luye Pharma Group Ltd.

Not yet recruiting

To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets

Major Depressive Disorder
Orygen
University of Melbourne; Youth Support and Advocacy Service

Recruiting

Guanfacine Extended-release for Adolescents With Cannabis Use (GRACE)

Cannabis Use Disorder

Australia
Yale University
National Institute of Mental Health (NIMH); Massachusetts General Hospital; University... and other collaborators

Completed

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

Pervasive Development Disorders

United States
Massachusetts General Hospital
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Completed

An Open Label Phase I/II Study of Dopamine Transporter Receptor Occupancy With OROS and Immediate Release Methylphenidate as Measured With C-11 Altropane in Human Subjects

Healthy Volunteers

United States
Rochester Center for Behavioral Medicine
Shire

Completed

Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65). (ADINT2012)

Adult Attention-Deficit Hyperactivity Disorder

United States
Tulane University
National Institute of General Medical Sciences (NIGMS)

Completed

Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial (NICE)

Chronic Kidney Disease

United States

3

Subscribe